Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 2 of 2
Full-Text Articles in Medicine and Health Sciences
Functional Network Resilience To Pathology In Presymptomatic Genetic Frontotemporal Dementia, Timothy Rittman, Robin Borchert, Simon Jones, John Van Swieten, Barbara Borroni, Daniela Galimberti, Mario Masellis, Maria Carmela Tartaglia, Caroline Graff, Fabrizio Tagliavini, Giovanni B. Frisoni, Robert Laforce, Elizabeth Finger, Alexandre Mendonça, Sandro Sorbi, Jonathan D. Rohrer, James B. Rowe, Sónia Afonso, Maria Rosario Almeida, Sarah Anderl-Straub, Christin Andersson, Anna Antonell, Silvana Archetti, Andrea Arighi, Mircea Balasa, Myriam Barandiaran, Nuria Bargalló, Robart Bartha, Benjamin Bender, Luisa Benussi, Valentina Bessi, Giuliano Binetti
Functional Network Resilience To Pathology In Presymptomatic Genetic Frontotemporal Dementia, Timothy Rittman, Robin Borchert, Simon Jones, John Van Swieten, Barbara Borroni, Daniela Galimberti, Mario Masellis, Maria Carmela Tartaglia, Caroline Graff, Fabrizio Tagliavini, Giovanni B. Frisoni, Robert Laforce, Elizabeth Finger, Alexandre Mendonça, Sandro Sorbi, Jonathan D. Rohrer, James B. Rowe, Sónia Afonso, Maria Rosario Almeida, Sarah Anderl-Straub, Christin Andersson, Anna Antonell, Silvana Archetti, Andrea Arighi, Mircea Balasa, Myriam Barandiaran, Nuria Bargalló, Robart Bartha, Benjamin Bender, Luisa Benussi, Valentina Bessi, Giuliano Binetti
Medical Biophysics Publications
© 2019 The Authors The presymptomatic phase of neurodegenerative diseases are characterized by structural brain changes without significant clinical features. We set out to investigate the contribution of functional network resilience to preserved cognition in presymptomatic genetic frontotemporal dementia. We studied 172 people from families carrying genetic abnormalities in C9orf72, MAPT, or PGRN. Networks were extracted from functional MRI data and assessed using graph theoretical analysis. We found that despite loss of both brain volume and functional connections, there is maintenance of an efficient topological organization of the brain's functional network in the years leading up to the estimated age …
Ambroxol As A Novel Disease-Modifying Treatment For Parkinson's Disease Dementia: Protocol For A Single-Centre, Randomized, Double-Blind, Placebo-Controlled Trial, C. R.A. Silveira, J. Mackinley, K. Coleman, Z. Li, E. Finger, R. Bartha, S. A. Morrow, J. Wells, M. Borrie, R. G. Tirona, C. A. Rupar, G. Zou, R. A. Hegele, D. Mahuran, Penny A. Macdonald, M. E. Jenkins, M. Jog, S. H. Pasternak
Ambroxol As A Novel Disease-Modifying Treatment For Parkinson's Disease Dementia: Protocol For A Single-Centre, Randomized, Double-Blind, Placebo-Controlled Trial, C. R.A. Silveira, J. Mackinley, K. Coleman, Z. Li, E. Finger, R. Bartha, S. A. Morrow, J. Wells, M. Borrie, R. G. Tirona, C. A. Rupar, G. Zou, R. A. Hegele, D. Mahuran, Penny A. Macdonald, M. E. Jenkins, M. Jog, S. H. Pasternak
Medical Biophysics Publications
© 2019 The Author(s). Background: Currently there are no disease-modifying treatments for Parkinson's disease dementia (PDD), a condition linked to aggregation of the protein α-synuclein in subcortical and cortical brain areas. One of the leading genetic risk factors for Parkinson's disease is being a carrier in the gene for β-Glucocerebrosidase (GCase; gene name GBA1). Studies in cell culture and animal models have shown that raising the levels of GCase can decrease levels of α-synuclein. Ambroxol is a pharmacological chaperone for GCase and is able to raise the levels of GCase and could therefore be a disease-modifying treatment for PDD. The …